No products in the cart.
Pre-made Datopotamab benchmark antibody ( Whole mAb, anti-TACSTD2 therapeutic antibody, Anti-EGP-1/EGP1/GA733-1/GA7331/GP50/M1S1/TROP2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-134
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Datopotamab biosimilar, Whole mAb, Anti-TACSTD2 Antibody: Anti-EGP-1/EGP1/GA733-1/GA7331/GP50/M1S1/TROP2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Datopotamab deruxtecan is an antibody drug conjugate (ADC), composed of an humanised anti-TROP2 monoclonal antibody and MAAA 1181a, a derivative of exatecan, a DNA topoisomerase I inhibitor, being developed by Daiichi Sankyo for the treatment of solid tumours including non-small cell lung cancer and breast cancer .
| Products Name (INN Index) | Pre-Made Datopotamab biosimilar, Whole mAb, Anti-TACSTD2 Antibody: Anti-EGP-1/EGP1/GA733-1/GA7331/GP50/M1S1/TROP2 therapeutic antibody |
|---|---|
| INN Name | Datopotamab |
| Target | TACSTD2 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Daiichi Sankyo |
| Conditions Approved | NA |
| Conditions Active | Breast cancer,Non-small cell lung cancer |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TACSTD2 |
| Package |
Previous slide
Next slide
